The Clinical trials of Chimeric Antigen Receptor T-cell (CAR-T) therapy was conducted worldwide. CAR-T Therapy has emerged as a breakthrough in cancer treatment. It has shown promising results on end stage patients, especially in patients of Acute Lymphocytic Leukemia.
- The technology has a remarkable therapeutic potential for cancer patients.
- This technology is not available in India, currently.
BIRAC (Biotechnology Industry Research Assistance Council) and DBT have initiated and launched specialised calls and invitation to promote and support development of CAR-T cell technology against cancer and other diseases.
The CAR-T cell therapy costs rupees 3-4 crore for each patient. Thus, biggest challenge is there to develop this technology in cost-effective manner and make it available patients. Manufacturing of this technology is complex which increases the cost.
First CAR-T cell Therapy
The First Therapy was done by IIT-Bombay and cancer care in India at Bone Marrow Transplant unit of Tata Memorial Centre in Mumbai. The CAR-T cells were designed and manufactured at Bioscience and Bioengineering department, IIT Bombay. This was also supported by BIRAC-PACE scheme. Now, this therapy will undergo Phase I and II trial of their CAR-T product through National Biopharma Mission.
First CAR-T Cell Therapy Conducted First CAR-T Cell Therapy Conducted